Hutchison China MediTech and AstraZeneca will expand the Phase II trial of their partnered c-MET inhibitor, savolitinib, triggering a $10 million milestone payment to Chi-Med. In 2011, AstraZeneca agreed to partner the Chi-Med discovered drug in a $140 million deal that included $20 million upfront and the rest in development milestones. At the time, savolitinib was said to be close to starting clinical trials. The two companies agreed to partner development in China, while AstraZeneca is responsible for global ex-China clinical work.
